ArticleBlood research2025

Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin's lymphoma.

Jun Ho Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.